Glaxosmithkline Pharmaceuticals Ltd Q1 FY27 Earnings Call: Guides 34% EBITDA Margin, Innovation Portfolio Share Doubles

Glaxosmithkline Pharmaceuticals Ltd held its Q1 FY27 earnings call on August 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue, Profit & Portfolio Mix

• Rs.924 Cr standalone sales in Q1 FY 2026-2027, up 15% YoY; adjusted for a softer base, sustainable growth was ~9-10%.
• EBITDA grew 17% to Rs.253 Cr with margins expanding 50 bps YoY to 27.4%; CFO guided EBITDA margins should settle around 34% for full FY 2026-2027, similar to the prior year.
• PAT grew 24% to Rs.253 Cr, margins up 200 bps to 27.6%; excluding a one-off dividend from subsidiary Biddle Sawyer, PAT growth would have been ~17%.
• Innovation portfolio contributed 7% of Q1 FY 2026-2027 revenue (share doubling YoY), adding 4 percentage points of headline growth; general medicines (GenMed) grew double-digit and gained market share.
• Gross margins improved 130 bps YoY, aided by pricing and product mix, partially offset by rupee depreciation on imported purchases.

Volume, Pricing & New Product Contributions

• Blended volume growth ~3-3.5% in Q1 FY 2026-2027, pricing contributed ~6%, balance from new product introductions.
• ~44-45% of GenMed portfolio under price control, limiting pricing flexibility; the Indian pharma industry grew 13.5% in Q1 FY 2026-2027 (volume 2%, balance from price and new launches).
• Shingrix grew 65% YoY in Q1 FY 2026-2027, with quarterly doses sold upwards of 45,000-50,000; MAT basis revenue exceeded Rs.100 Cr.
• Nucala patient base nearly tripled to 600 active patients as of Q1 FY 2026-2027, with the business almost doubling YoY; new patient addition rate doubled to 100-120 per month.
• Trelegy Ellipta maintained 10,000-12,000 monthly units despite 10-12 generic launches of the mid-linidium molecule.
• Phasing issue for a couple of vaccines in Q1 FY 2026-2027 expected to be corrected in Q2 FY 2026-2027.

Launch Progress, Addressable Markets & R&D Horizon

• 600-700 patients initiated on Zejula and Jemperli in H1 CY 2026 (250-300 per quarter), with oncology field force of 40-45 people hired within 11 months; productivity already "right up there."
• Zejula approved for first-line maintenance in ovarian cancer; Jemperli (Dostarlimab) for first-line endometrial cancer; a rectal cancer indication is being pursued but trials are ongoing (period unspecified).
• Belantamab (Blenrep) received DCGI approval for second-line relapsed/refractory multiple myeloma, targeting 7,000-8,000 patients annually; launch planned within FY 2026-2027, likely Q2 or Q3.
• Bepirovirsen for chronic hepatitis B — management cited "over 40 million chronic hepatitis B patients in India" as a key market; commercial strategy commentary deferred to Q2 FY 2026-2027.
• Arevixy (RXV) adult RSV vaccine — management cited a potential universe of "10-12 million adults aged 50+ with relevant disposable income" in India, but noted it is a new category requiring significant market-building.
• Pneumococcal 24-valent vaccine not a current priority for India; management confirmed "GSK is not part of its global trials" and key vaccine priorities remain two or three antigens including an mRNA flu platform.

Cost Structure, Front-Loaded Investments & Productivity

• 36% YoY Opex rise in Q1 FY 2026-2027 attributed to deliberate front-loading of promotional activities (speaker programs, medical oncologist visits); management expects Opex growth to normalize in subsequent quarters.
• EBITDA grew 17% YoY despite the Opex spike (vs. 15% sales growth), with margins expanding; CFO guided SG&A ratios should normalize and EBITDA margins settle around 34% for FY 2026-2027.
• Blended MR productivity of Rs.15-16 lakhs per rep, improving 5-6% in Q1 FY 2026-2027; current field force of ~2,000 in General Medicines and ~200 in Established Vaccines deemed appropriate.
• Future hiring to target new therapeutic areas with little or no current presence, specifically mentioning liver disease; incremental field force additions will be directed there.
• Supply chain issues for Calpol (CMO incident at Baddi) resolved; underlying adjusted growth remained double-digit in Q1 FY 2026-2027.

Medium-Term Targets, Guidance & External Context

• Management confirmed medium-term aspiration to reach Rs.8,000 Cr top line in 4 to 5 years (implying a target horizon of ~FY 2030-2031 or FY 2031-2032), requiring a 13-14% CAGR; this was referenced by an analyst, not issued as formal guidance.
• Established business (GenMed + vaccines) expected to grow 8-10%; new launches in high-growth segments like oncology (which grew 27% in Q1 FY 2026-2027 vs. industry 12-13%) will serve as the "arrowhead."
• Management declined specific forward-looking guidance on sustainable growth rates for FY 2026-2027 or beyond, stating the overriding objective is to sustain "double-digit momentum."
• Q2 FY 2026-2027 acute season tracking in line with expectations based on June and July data; acute segment contributes 60% of the Indian pharma market.
• India-EU FTA or UK FTA has no immediate bearing on GSK India operations due to its "local for local" model; existing Nashik facility and 20 contract manufacturers already produce bulk of GenMed locally, supporting the Rs.4,000 Cr revenue in FY 2025-2026.
• Management does not foresee any immediate impact from the post-West Asia war situation on raw material or packaging costs, citing well-embedded global supply chains.